Adalimumab biosimilars in the therapy of Crohn’s disease and ulcerative colitis: Prospective multicentric clinical monitoring

Martin Wasserbauer¹, Stepan Hlava¹*¹, Jiri Drabek¹, Jan Stovicek¹, Petra Minarikova², Lenka Nedbalova³, Tomas Drasar³, Zdena Zadorova⁴, Jiri Dolina⁵, Stefan Konecny⁵, Vladimir Kojecky⁶, Jana Kozeluhova⁷, Pavlina Cernikova¹, Dita Pichlerova¹, Barbora Kucerova³, Stepan Coufal⁹, Radan Keil¹

¹ Department of Internal Medicine, 2nd Faculty of Medicine, Motol University Hospital, Charles University in Prague, Prague, Czech Republic, ² Department of Internal Medicine, 1st Faculty of Medicine, Military University Hospital, Charles University in Prague, Prague, Czech Republic, ³ Department for the Treatment of Non-specific Intestinal Inflammations - IBD Center Turnov, Hospital Turnov, Turnov, Czech Republic, ⁴ 2nd Department of Internal Medicine, 3rd Faculty of Medicine, FKNV, Charles University in Prague, Prague, Czech Republic, ⁵ Department of Internal Medicine and Gastroenterology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic, ⁶ Department of Internal Medicine, Regional Hospital of T. Bata, Zlin, Czech Republic, ⁷ 2nd Department of Internal Medicine, University Hospital Plzen - Bory, Plzen, Czech Republic, ⁸ Department of Pediatric Surgery, 2nd Faculty of Medicine, University Hospital Motol, Charles University in Prague, Prague, Czech Republic, ⁹ Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic

* stepan.hlava@fnmotol.cz

Abstract

Objective
The adalimumab biosimilars FKB327 and GP2017 were approved for the therapy of patients with inflammatory bowel disease (IBD). Relatively few prospective studies with biosimilar adalimumab in patients with IBD have been published. The aim of this prospective observational study was to evaluate the effectiveness and safety of the biosimilar adalimumab.

Material and methods
Adalimumab biosimilars FKB327 (Hulio®) and GP2017 (Hyrimoz®) were indicated to 50 naive patients in terms of biological therapy with Crohn’s disease (CD) or ulcerative colitis (UC). Effectiveness of therapy was evaluated via the Crohn’s Disease Activity Index [CDAI] or the Mayo Scoring System [MSS] in patients with CD or UC, respectively, before and after 12 weeks. Additional goals were to evaluate weight changes, laboratory tests and complications or adverse events of this therapy.

Results
In CD patients, remission (CDAI <150) was achieved in 73.5% of cases, partial response (≥70-point decrease in CDAI score from baseline) in 11.8%, no response in 11.8% and 2.9% patients discontinued therapy. In UC patients, remission (total score on partial Mayo index ≤2 points) was achieved only in 18.8% of cases, partial response (≥2-point decrease
in partial Mayo score from baseline) in 43.8%, no response in 25.0% and 12.5% patients discontinued therapy. There were statistically significant improvements in CDAI, MSS, haemoglobin, fecal calprotectin, albumin and CRP serum levels after 12 weeks of therapy. Seven adverse events were identified, three of which resulted in therapy being discontinued.

Conclusions
This prospective observational study proved the effectiveness of the adalimumab biosimilars FKB327 and GP2017 in IBD.

Introduction
Crohn’s disease and ulcerative colitis, which are two major forms of inflammatory bowel disease (IBD), are chronic immune-mediated diseases that are characterized by periods of remission and relapse [1, 2]. Management of IBD therapy is focused on inducing and then maintaining remission. Anti-TNFα agents, as the first used group of biological therapy, opened up a new era in IBD therapy [2]. Adalimumab, as one of the basic representatives of the group of anti-TNFα agents, is a recombinant fully humanised monoclonal IgG1 antibody directed against TNFα administered subcutaneously. The efficacy of adalimumab, repeatedly demonstrated in many studies, has found an indisputable place in the therapy of patients with especially severe forms Crohn’s disease and ulcerative colitis [3–8].

Biological drugs have a significantly more complex structure than conventional drugs. The crucial distinction is not only the primary structure of the molecule but also the secondary and tertiary structure, as well as post-translational changes, biological and immunochemical properties. Due to the complex structure of the molecule and its properties, it is practically impossible to make an identical copy of the original molecule of a biological drug. Biosimilars are not the same as generic versions of small-molecule drugs. Generics have relatively simple chemical structures and can thus be manufactured to be identical to their originator drug, in contrast to biological drugs. Biosimilar drugs can therefore be defined as highly similar drugs (not the same) to their originator biological drug [9, 10]. Determining the "high similarity" of biosimilar drugs is part of comprehensive and extensive comparability programs [9–12]. Extensive analytical tests are initially performed to confirm the high functional, physico-chemical and structural similarity of the biosimilar drug to the original product [13]. This is followed by a clinical trial phase in which comparable efficacy and safety are verified. This clinical trial is performed for a single indication of the original biological drug. When proving the effectiveness of safety in this one indication, the data are extended (so-called extrapolated) to other indications of the original biological product [14, 15].

The adalimumab biosimilars FKB327 (Hulio®) and GP2017 (Hyrimoz®) are now available for clinical use in IBD (CD and UC) in many countries all over the world. These adalimumab biosimilars have been approved in many countries in all indications as an original biological drug. Extensive laboratory non-clinical comparability exercises with FKB327 and GP2017 were made which demonstrated high similarity with original adalimumab. Subsequently, the effectiveness and safety of FKB327 and GP2017 were proved in two large clinical studies (GP2017 in patients with psoriasis and FKB327 in patients with rheumatoid arthritis) and therapeutic indications were then extrapolated to all indications as with original adalimumab [16, 17]. To this date, there are relatively few published reports regarding clinical outcomes achieved with biosimilar adalimumab in patients with CD and/or UC.
The primary outcome of this prospective observational study was to evaluate the effectiveness of FKB327 (Hulio\textsuperscript{R}) and GP2017 (Hyrimoz\textsuperscript{R}) in terms of response to induction treatment in patients with CD or UC after 12 weeks of therapy. The effectiveness of therapy was evaluated individually using the Crohn’s Disease Activity Index (CDAI) in patients with CD or the Mayo Scoring System (MSS) in patients with UC. The additional outcomes of this study were to evaluate the trends in values of some laboratory tests (CRP, fecal calprotectin, leukocytes, albumin and others), the weight profile of patients and endoscopic findings during therapy, complications or adverse effects of this biological therapy as well as differences in effectiveness between FKB327 (Hulio\textsuperscript{R}) and GP2017 (Hyrimoz\textsuperscript{R}).

**Materials and methods**

**Patients**

Our prospective observational study (clinical monitoring) was performed at 7 Gastroenterology departments across the Czech Republic in outpatients older than 18 years of age. The study was performed between 6/2019–8/2021.

Inclusion criteria for this study: Indication of Biosimilar adalimumab FKB327 (Hulio\textsuperscript{R}) or GP2017 (Hyrimoz\textsuperscript{R}) in naive patients (in terms of biological therapy) with CD or UC if indication criteria for these biological agents (according to the guidelines of the Czech Gastroenterological Society valid at the time of study) were met [18–20]. FKB327 and GP2017 were indicated in patients for treatment of:

1. CD, in case of: severe form of CD after failure of conventional therapy (especially thiopurines or methotrexate), perianal fistulas, corticosteroid course of CD, high risk of unfavourable course of CD, some extraintestinal manifestations of CD and early recurrence of CD after surgical resection.
2. UC, in case of: moderate to severe active form of UC after failure of conventional therapy (especially thiopurines or methotrexate), acute severe UC attack (so-called rescue therapy), corticosteroid course of UC, and some extraintestinal manifestations of UC.

Exclusion criteria for this study were: previous biological therapy, complications of IBD leading to surgery (strictures, abscess or perforations), contraindication(s) for biological therapy with adalimumab, or patient disagreement with biological therapy.

The study included patients from all participating centers who met the inclusion criteria from June 2019 to August 2021. The choice between particular type of biosimilar adalimumab (FKB327 or GP2017) depended only on availability within the individual centers involved in our study. Only one type of biosimilar adalimumab was available at each participating center (FKB327 or GP2017) and, consequently, only one biosimilar adalimumab was administered in that center. No active selection or randomization was made. Instead, the participating centers were initially chosen with respect to the type of biosimilar adalimumab administered so that the ratio between the two types of biosimilar adalimumab (as well as between the number of patients in a center) could be expected to be approximately the same and thus compared. During the study period, all patients received the treatment originally assigned at the beginning; there were no changes in the type of biosimilar adalimumab administered (FKB327 or GP2017). The minimum size of the examined group of patients was predetermined before the initialization of our study based on the recommendation of a statistician (groups of patients ≥40 due to statistical evidence) while the definitive size of our patient groups was determined by the recruitment of patients in the centers and the time schedule of the study. Subsequently, all data were collected at weeks 0 and 12 and then summarized and analysed.
Patients were allowed to use other therapy for IBD before biological therapy and concomitant therapy during therapy of biosimilar adalimumab.

Methods

Patients fulfilling the inclusion criteria (men and women) with IBD (CD or UC) were assigned to biological therapy with FKB327 (Hulio®) or GP2017 (Hyrimoz®) in a classical induction scheme (160 mg at Week 0, 80 mg at Week 2 and then 40 mg every two weeks via subcutaneous injection). Patients were monitored for 12 weeks (7 doses of biosimilar adalimumab in total) after which they were given the option to continue with the biosimilar adalimumab therapy. However, data on treatment beyond Week 12 are not presented here.

At the beginning of clinical monitoring, patients were asked to answer some basic questions focusing on details of their disease and therapy in order to collect information on baseline demographics and characteristics. Additionally, laboratory samples (blood count, albumin, liver tests, CRP fecal calprotectin from stool) were taken. Each patient also underwent an endoscopy before study enrolment and was weighed. CDAI in patients with CD or MSS in patients with UC was counted.

The observed parameters (CDAI in patients with CD, MSS in patients with UC, CRP and other laboratory tests, weight and endoscopic findings) were assessed after 12 weeks of therapy.

In patients with CD, a partial response was defined as a $\geq$70-point decrease from the baseline in CDAI score and remission was defined as a CDAI score of $< 150$. In patients with UC, a partial response was defined as a $\geq$2-point decrease from the baseline in a partial Mayo score and remission was defined as a total score on the partial Mayo index of $\leq 2$ points. Patients who did not show a partial response or remission were considered non-responders.

The study protocol was approved by the ethics committee of the Second Faculty of Medicine, Charles University in Prague, Czech Republic and each patient provided signed consent to this study prior to being accepted.

Statistical analyses

The variables were tested for normality by a Shapiro-Wilcoxon normality test and the differences between studied groups were analysed by either a Paired T-test or a Wilcoxon matched-pairs signed rank test. Fisher’s exact test was used to determine the association between two categorical variables. Statistical analyses were performed using GraphPad Prism version 6.0 (GraphPad Software, GraphPad Software, San Diego, CA, USA) and differences were considered statistically significant at $p < 0.05$.

Results

Patient demographics (Table 1)

In our study, fifty eligible patients (31 men and 19 women) with CD (34 patients) or UC (16 patients) were enrolled. The median patient age was 39.5 and the range was between 20–74 years of age. The median age of patients at first diagnosis and first manifestation of IBD were both 27.0 years.

In the CD group extent of disease was: only colon (4 patients), only small intestine (11 patients), both small bowel and colon (19 patients). Fistulas in CD patient’s anamneses were also reported: perianal fistulas (13 patients), enteroenteral fistulas (2 patients) and rectovaginal fistula (1 patient). In the UC group extent of disease was: E3 (pancolitis) was present in 12 patients and E2 (left-sided colitis) was present in 4 patients. Extraintestinal manifestations of
IBD were reported by 15 patients (joints in 12 and skin in 3 patients). Finally, history of surgery was reported in 18 patients (ileocecal resection in 10 patients, right-sided hemicolectomy in 5 patients, stricturoplasty in 2 patients and subtotal colectomy in 1 patient).

Prior to biological therapy with biosimilar adalimumab, 46 patients had received 5-aminosalicylates, 50 oral corticosteroids, 48 azathioprine and 8 methotrexate. In terms of concomitant therapy during biosimilar adalimumab therapy, 30 patients were treated with 5-aminosalicylates, 16 with low-dose systemic corticosteroids, 24 with azathioprine and 1 with methotrexate.

All patients received either FKB327 (Hulio®, 22 patients) or GP2017 (Hyrimoz®, 28 patients) subcutaneously at Week 0 (160mg), Week 2 (80mg), Week 4 (40mg), Week 6 (40mg), Week 8 (40mg), Week 10 (40mg) and Week 12 (40mg) in a classical scheme.

### Crohn’s disease—Effectiveness

In the CD group (34 patients): 25 patients (73.5%) achieved remission and 4 patients (11.8%) partial response after 12 weeks of therapy. Four patients (11.8%) were classified as non-responders to therapy with biosimilar adalimumab. One patient from this group discontinued therapy prior to Week 12 because of an adverse event (paraesthesia of all extremities, based on EMG neurogenic lesion).

The median CDAI value in the CD group before therapy was 216.0 and this decreased to 110.0 (p<0.0001) after 12 weeks of therapy (Fig 1A).
Fig 1.  **A**: The trend of CDAI values in the CD group before and after 12 weeks of therapy. **B**: The trend of MSS values in the UC group before and after 12 weeks of therapy.

https://doi.org/10.1371/journal.pone.0271299.g001
Ulcerative colitis—Effectiveness

In the UC group (16 patients), only 3 patients (18.8%) achieved remission and 7 patients (43.8%) partial response after 12 weeks of treatment. Four patients (25.0%) showed no response to therapy. Two patients discontinued therapy prior to Week 12, both due to allergic reaction.

The median MSS value in the UC group before therapy was 8.0 and this decreased to 4.0 (p = 0.0003) after 12 weeks of therapy (Fig 1B).

Crohn’s disease and ulcerative colitis—Other parameters

The median of weight before therapy was 80.0 kg, but this decreased to 78.0 kg after 12 weeks of therapy.

Trends in laboratory parameters were also compared before and in Week 12 of therapy: CRP 6.7 mg/l and 2.0 mg/l respectively (p < 0.0001) (Fig 2A), albumin 43.2 g/l and 44.1 g/l respectively (p = 0.003) (Fig 2A), ALP 1.2 μkat/l and 1.1 μkat/l respectively (p = 0.8390), AST 0.4 μkat/l and 0.42 μkat/l respectively (p = 0.6260), ALT 0.4 μkat/l and 0.5 μkat/l respectively (p = 0.4543), GGT 0.6 μkat/l and 0.6 μkat/l respectively (p = 0.5794), total bilirubin 10.7 μmol/l and 9.0 μmol/l respectively (p = 0.7902), urea 4.2 μmol/l and 4.0 μmol/l respectively (p = 0.4127), creatinin 78.5 μmol/l and 80.9 μmol/l respectively (p = 0.5802), leukocytes

(A)

(B)

Fig 2. A: The trend of CRP and ALBUMIN before and after 12 weeks of therapy. B: The trend of HEMOGLOBIN and FECAL CALPROTECTIN before and after 12 weeks of therapy.

https://doi.org/10.1371/journal.pone.0271299.g002
8.9 x10⁹/l and 8.2 x10⁹/l respectively (p = 0.0274), haemoglobin 133.0 g/l and 139.0 g/l respectively (p <0.0001) (Fig 2B), thrombocytes 330.0 x10⁹/l and 282.0 x10⁹/l respectively (p <0.0001) and fecal calprotectin 376.0 μg/g and 118.5 μg/g respectively (p = 0.0004) (Fig 2B).

In patients who achieved remission, the most noticeable effect was observed after the 6th dose while in patients with partial responses after the 4th dose of therapy.

**FKB327 (Hulio®) and GP2017 (Hyrimoz®) differences**

In 22 IBD patients treated with FKB27(Hulio®) and 28 patients treated with GP2017 (Hyrimoz®), remission or partial response was achieved in 18 patients (81.8%) and in 21 patients (75.0%), respectively, after 12 weeks of therapy (p = 0.7344).

In the FKB27(Hulio®) group, the median of CDAI value in the CD group before therapy was 201.0 while the median of MSS value in the UC group before therapy was 6.0, after 12 weeks of therapy this decreased to 110.0 (p<0.0001) and 3.5 (p = 0.1250), respectively.

In the GP2017 (Hyrimoz®) group, the median of CDAI value in the CD group before therapy was 251.0 while the median of MSS value in the UC group before therapy was 8.0, after 12 weeks of therapy this decreased to 110.5 (p = 0.003) and 4.0 (p = 0.0056) respectively.

**Safety and tolerability**

Seven adverse events were identified during the therapy: in four patients mild complications were observed (one patient with skin eczema, one patient with mild course of COVID-19, one patient with mild course of mycotic infection and one patient with mild course of pneumonia) and in three patients (1 with CD and 2 with UC) the therapy was discontinued as described above.

**Discussion**

Adalimumab is indicated in IBD patients with: moderate to severe active CD that is refractory to conventional treatment, corticodependence and some extraintestinal manifestations; additionally, in CD patients with perianal fistulas and in UC as a rescue therapy in case of acute severe UC attack [19, 20]. The effectiveness of adalimumab RMP in induction of remission in patients with IBD has been demonstrated in many studies. The CLASSIC I study played a crucial role in demonstrating efficacy in inducing remission in patients with CD—a response rate at Week 4 was based on dosages of 40 mg/20 mg, 80 mg/40 mg, and 160 mg/80 mg 18%, 24% and 36% respectively [21]. The study ULTRA 1 in patients with UC played a similarly crucial role in the induction of remission—at week 8 18.5% of patients in the adalimumab 160 / 80mg group and 10.0% in the adalimumab 80 / 40mg group were in remission compared with 9.2% in the placebo group [6]. Aware of the differences between our methodology and these studies, our data showed in CD and UC high effectiveness of biosimilar adalimumab in inducing remission—in the CD group 85.3% of patients and in the UC group 62.6% of patients achieved remission or partial response. Our data suggest a poorer efficacy of biosimilar adalimumab in patients with ulcerative colitis.

The first biosimilar in IBD therapy was the biosimilar equivalent of infliximab (CT-P13), developed by Celltrion. CT-P13 was approved by the European Medicine Agency (EMA) in 2013. Many authors have provided data on the efficacy and safety of the biosimilar infliximab CT-P13 in patients with Crohn’s disease and ulcerative colitis [22–24]. Keil et al. provides evidence of the effectiveness of CT-P13 in IBD patients in induction of remission [23] and Schmitz et al. also proved efficiency and safety in 12-month follow-up [24]. The first biosimilar analog of adalimumab was approved by EMA in all indications of the original product in April 2017. Efficacy and safety data for biosimilar adalimumab FKB327 (Hulio®) and GP2017
(Hyrimoz\textsuperscript{R}) for patients with Crohn’s disease or ulcerative colitis were extrapolated from efficiency and safety data in patients with rheumatological or dermatological problems [16, 17]. The available data on the efficacy and safety of the biosimilar adalimumab directly in patients with inflammatory bowel disease are limited and include, in particular, retrospective studies with a small number of patients. Kamat et al. (India) proved safety and efficiency in inducing and maintaining remission in 70 patients with ulcerative colitis or Crohn’s disease [25]. Efficiency in inducing remission was achieved in 46.9% of CD patients and 52.4% of UC patients and maintained remission over 1 year was achieved in 32.7% of CD and 33.3% of UC patients.

In our UC group of patients 18.8% of patients achieved remission and 43.8% of patients achieved partial response after 12 weeks of therapy. The data are consistent with the conclusions of Chandra et al. (India), who evaluated the efficacy and safety of the adalimumab biosimilar ZRC-3197 (Exemptia) in 25 patients with steroid-refractory ulcerative colitis. In this study clinical remission was achieved in 16% of patients at 12 and 24 weeks and clinical response in 48% of patients at week 12 and 44% at week 24 [26]. Chandra et al. also described a statistically significant decrease of MSS (MSS at baseline 10.16 points, MSS at week 12 5.72 points and MSS at week 24 5.52 points). These data are consistent with our results—the median of MSS value in our UC group before therapy was 8.0 and then decreased to 4.0 after 12 weeks of therapy with biosimilar adalimumab.

In our CD group 73.5% of patients achieved remission and 11.8% of patients achieved partial response after 12 weeks of therapy. Ribaldone et al. achieved more or less similar results in a study of 25 patients with CD naive patients to biosimilar adalimumab ABP 501—clinical response at 3 months was achieved in 60% of CD patients and clinical remission at 3 months in 56% of CD patients [27].

In line with our results, a comparison with the results of our previously performed study with the biosimilar infliximab CT-P13 and its effectiveness in inducing remission appears to be highly interesting [23]. The advantage is the possibility of a good comparison of both studies with respect to the similar design of these two studies. In a study with the biosimilar infliximab CT-P13 in patients with CD at week 14 remission was achieved in 50.0% of cases with partial response in the remaining 50.0%. In our recent biosimilar adalimumab CD group 73.5% of patients achieved remission and 11.8% of patients achieved partial response after 12 weeks of therapy. In the UC group, patients treated with biosimilar infliximab achieved remission in 40.9% of cases and partial response in 54.5%. In our recent biosimilar adalimumab UC group only 18.8% of patients achieved remission and 43.8% of patients achieved partial response. Based on these results, induction therapy with biosimilar infliximab CT-P13 appears to be more effective in inducing remission in patients with both CD and UC rather than induction therapy with biosimilar adalimumab. To the best of our knowledge, this seems to be the first comparison of biosimilar infliximab and biosimilar adalimumab in induction remission in biologically naive patients with inflammatory bowel disease.

In our study, two types of biosimilar adalimumab were used: FKB327 (Hulio\textsuperscript{R}) and GP2017 (Hyrimoz\textsuperscript{R}). There was no statistically significant difference in the efficacy of induction therapy between these two medicaments (remission or partial response of 81.8% in FKB27 vs. 75.0% in GP2017). Only in the FKB27 group, the median of MSS value decrease was not statistically significant compared to other results—however, we do not consider this result to be clinically significant.

Many parameters were carefully monitored during our study. The evaluation of efficiency in our study was based mainly on the trend of activity indexes. Statistically significant decreases in values of CDAI in CD and MSS in UC were demonstrated in our groups of patients. In the CD group, the median CDAI before therapy was 216.0 and after 12 weeks of therapy decreased to 110.0. CDAI is one of the widely used clinical activity indexes, whose
invaluable role has been demonstrated in a number of studies [28–30]. Also, within the UC group, the median of MSS value decreased from 8.0 to 4.0. MSS is relatively simple to use in clinical practice and also in clinical trials [31]. In addition to the response data collected in the current study, our patients also showed a significant decrease in CRP, fecal calprotectin and leukocytes values. Furthermore, increases in the serum albumin and haemoglobin were statistically significantly present. The elevation of CRP could be associated with higher clinical severity of disease much more strongly in patients with CD than UC—low levels of CRP do not rule out the presence of active disease, especially in patients with UC [32]. In patients with CD, higher levels may be associated with a higher risk of relapse or failure of biological therapy [33, 34]. Fecal calprotectin appears to be a very suitable marker for the evaluation of clinical and endoscopic activity of both CD and UC [35–37]. Zittan et al. clearly demonstrated the correlation between MSS and fecal calprotectin values [37], which agrees with our conclusions. Other monitored parameters (leucocytosis, haemoglobin and albumin) are commonly used markers of disease activity in a broader sense. These parameters do not have an irreplaceable role in patient monitoring and provided only additional information about the patient’s condition [38].

A biological therapy with antiTNFα therapy is relatively safe, but can be associated with potentially serious adverse effects. Seven adverse events occurred during our study—in percentage terms, 14% of patients in our group. Four of these were classified as a mild infection, which did not lead to discontinuation of therapy. Different kinds of viral, bacterial or fungal infections could be associated with the use of biological therapy with antiTNFα in IBD and can occur in up to one third of patients with antiTNFα [39, 40]. Therapy of biosimilar adalimumab had to be discontinued (two allergic reactions, one neurological complication) in three of seven adverse reactions (6% of all patients), which is practically the same as in the original adalimumab studies. In the CHARM study 6.3% of patients with CD discontinued therapy with adalimumab because of an adverse event [41]. In comparison to the study by Kamat et al. with biosimilar adalimumab, where the adverse reaction was present in 28.6% of patients and severe in 10% of patients, there were significantly fewer treatment-associated adverse reactions in our study [25]. On the other hand, in our study with the biosimilar infliximab CT-P13, adverse reactions were present in only 7.7% of patients [23].

Limitations of this study are mainly: a relatively small number of included patients, non-randomised and non-blinded design of our study. However, despite these limitations, our results show positive clinical outcomes following administration of biosimilar adalimumab to IBD patients.

In conclusion, our prospective observational multicentric study proved the effectiveness and safety of adalimumab biosimilars FKB327 and GP2017 in the therapy of patients with Crohn’s disease and ulcerative colitis. However, larger, double-blind, randomised, prospective, long-term studies are necessary to be done to provide further data about efficiency and safety of therapy with biosimilar adalimumab.

Supporting information
S1 Table. Source data of this study divided into three tables. (XLSX)

Author Contributions
Conceptualization: Martin Wasserbauer, Jan Stovicek, Radan Keil.
Data curation: Martin Wasserbauer.
Formal analysis: Martin Wasserbauer, Dita Pichlerova.

Investigation: Martin Wasserbauer, Jan Stovicek, Petra Minarikova, Lenka Nedbalova, Tomas Drasar, Zdena Zadorova, Jiri Dolina, Stefan Konecny, Vladimir Kojecky, Jana Kozeluhova, Pavlina Cernikova, Barbora Kucerova.

Methodology: Stepan Coufal.

Supervision: Jiri Drabek, Jan Stovicek, Radan Keil.

Writing – original draft: Martin Wasserbauer.

Writing – review & editing: Stepan Hlava.

References

1. Podolsky DK, Camilleri M, Fitz JG, Kalloo AN, Shanahan F, Wang TC et al. Yamada’s Textbook of Gastroenterology, 6th edition, John Wiley & Sons, New Jersey, 2016; 1364–1377.
2. Feldman M, Friedman L, Brandt L, Chung RT, Rubin DT, Wilcox CM et al. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology, diagnosis, management, 11th edition. Elsevier, Philadelphia: 2016; 1868–1897.
3. Feagan BG, Panaccione R, Sandborn WJ, D’Haens GR, Schreiber S, Rutgeerts PJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology. 2008 Nov; 135(5):1493–9. https://doi.org/10.1053/j.gastro.2008.07.069 Epub 2008 Aug 3. PMID: 1848553.
4. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644–59, quiz 660. https://doi.org/10.1038/ajg.2011.73 Epub 2011 Mar 15. PMID: 21407183.
5. Taxonera C, Estellés J, Fernández-Blanco I, Merino O, Marín-Jiménez I, Barreiro-de Acosta M, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011 Feb; 33(3):340–8. https://doi.org/10.1111/j.1365-2036.2010.04531.x Epub 2010 Dec 7. PMID: 21133961.
6. Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780–7. https://doi.org/10.1136/gut.2010.221127 Epub 2011 Jan 5. PMID: 21299123.
7. Chen X, Hou J, Yuan Y, Huang C, Liu T, Mo C, et al. Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. BioDrugs. 2016 Jun; 30(3):207–17. https://doi.org/10.1007/s40265-016-0173-6 PMID: 27120055.
8. Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from the ULTRA 1, 2, and 3. Am J Gastroenterol. 2014 Nov; 109(11):1771–80. https://doi.org/10.1038/ajg.2014.242 Epub 2014 Aug 26. PMID: 25155227.
9. Declerck P, Danesi R, Petersel D, Jacobs I. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. Drugs. 2017 Apr; 77(6):671–677. https://doi.org/10.1007/s40265-017-0717-1 PMID: 28258517.
10. Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, et al. Policies for biosimilar uptake in Europe: An overview. PLoS One. 2017 Dec 28; 12(12):e0190147. https://doi.org/10.1371/journal.pone.0190147 PMID: 29284064.
11. Ishii-Watabe A, Kuwabara T. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metab Pharmacokinet. 2019 Feb; 34(1):64–70. https://doi.org/10.1016/j.dmpk.2018.11.004 Epub 2018 Dec 7. PMID: 30600193.
12. Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Interchangeability of Biosimilars: A European Perspective. BioDrugs. 2017 Apr; 31(2):83–91. https://doi.org/10.1007/s40265-017-0210-0 PMID: 28120313.
13. Sullivan PM, DiGrazia LM. Analytic characterization of biosimilars. Am J Health Syst Pharm. 2017 Apr 15; 74(8):568–579. https://doi.org/10.2146/ajhp150971 PMID: 28389456.
14. Tesser JR, Furst DE, Jacobs I. Biosimilars and the extrapolation of indications for inflammatory conditions. Biologics. 2017 Feb 17; 11:5–11. https://doi.org/10.2147/BT.214476 PMID: 28255229.
15. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014 Nov 20; 124(22):3191–6. https://doi.org/10.1182/blood-2014-06-583617 Epub 2014 Oct 8. PMID: 25298038.

16. Genovese MC, Glover J, Greenwald M, Porawska W, El Khouri EC, Dokoupilova E, et al. FKBB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Arthritis Res Ther. 2019 Dec 12; 21(1):281. https://doi.org/10.1186/s13075-019-2046-0 PMID: 31831079.

17. Blauvelt A, Lacour JP, Fowler JF Jr, Weinberg JM, Gospodinov D, Schuck E, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018 Sep; 179(3):623–631. https://doi.org/10.1111/bjd.16890 Epub 2018 Jul 15. PMID: 29917226.

18. Bortlik M, Řůnicová D, Douda T, Konecný M, Kozeluhová J, Novotný A et al. Guidelines for the administration of biological therapy in patients with inflammatory bowel diseases: Fourth, updated edition. Gastroenterologie a hepatologie. 2018, 73:11–24.

19. Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2020 Jan 1; 14(1):4–22. https://doi.org/10.1093/ecco-jcc/jjz180 PMID: 31711158.

20. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017 Jul 1; 11(7):769–784. https://doi.org/10.1093/ecco-jcc/jjx009 Erratum in: J Crohns Colitis. 2017 Dec 4;11(12):1512. PMID: 28513905.

21. Hanauer SB, Sandborn WJ, Rutgeerts P, Lukas M, Macintosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb; 130(2):323–33; quiz 591. https://doi.org/10.1053/j.gastro.2005.10.030 PMID: 16472588.

22. Farkas K, Rutka M, Ferenci T, Nagy F, Bálint A, Bor R, et al. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis—experiences from a single center. Expert Opin Biol Ther. 2017 Nov; 17(11):1325–1332. https://doi.org/10.1080/14712598.2017.1363885 Epub 2017 Aug 18. PMID: 28819991.

23. Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, et al. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis. Scand J Gastroenterol. 2016 Sep; 51(9):1062–8. https://doi.org/10.3109/00365521.2016.1149883 Epub 2016 Mar 22. PMID: 27002981.

24. Schmitz EMH, Boekema PJ, Straathof JWA, van Rensburg DC, Bruinsveld L, Scharnhorst V, et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther. 2018 Feb; 47 (3):356–363. https://doi.org/10.1111/apt.14453 Epub 2017 Dec 5. PMID: 29205444.

25. Kamat N, Kedia S, Ghoshal UC, Nehra A, Makharia G, Sood A, et al. Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study. Indian J Gastroenterol. 2019 Feb; 38(1):44–54. https://doi.org/10.1007/s12664-018-0922-1 Epub 2019 Jan 15. PMID: 30645725.

26. Chandra A, Kanth R, Thareja S. Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up. Biologics. 2019 Nov 25; 13:191–200. https://doi.org/10.2147/BTT.S214518 PMID: 31819364.

27. Ribaldone DG, Caviglia GP, Pellicano R, Vernero M, Saracco GM, Morino M, et al. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn’s disease: an observational study. Rev Esp Enferm Dig. 2020 Mar; 112(3):195–200. https://doi.org/10.17235/reeed.2020.6693/2019 PMID: 32054272.

28. Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019 Mar 26; 13(3):273–284. https://doi.org/10.1093/ecco-jcc/jjy114 PMID: 30137278.

29. Papay P, Ignjatovic A, Karmiris K, Amarante H, Miheller P, Feagan B, et al. Optimising monitoring in the management of Crohn’s disease: a physician’s perspective. J Crohns Colitis. 2013 Sep; 7(8):653–69. https://doi.org/10.1016/j.crohns.2013.02.005 Epub 2013 Apr 4. PMID: 23562672.

30. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn’s disease: monitoring disease activity. Aliment Pharmacol Ther. 2003 Jun; 17 Suppl 2:11–7. https://doi.org/10.1046/j.1365-2036.2003.s2.17.x PMID: 12786607.

31. D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb; 132(2):763–86. https://doi.org/10.1053/j.gastro.2006.12.038 Epub 2006 Dec 20. PMID: 17258735.
32. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015 Jun; 110 (6):802–19; quiz 820. https://doi.org/10.1038/ajg.2015.120 Epub 2015 May 12. PMID: 25964225.

33. Consigny Y, Modigliani R, Colombel JF, Dupas JL, Lémann M, Mary JY; Groupe d’Études Thérapeutiques des Affections Inflammatoires Digestives (GETAID). A simple biological score for predicting low risk of short-term relapse in Crohn’s disease. Inflamm Bowel Dis. 2006 Jul; 12(7):551–7. https://doi.org/10.1097/IBD.0b013e318015779a.

34. Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, et al. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. J Crohns Colitis. 2015 Jul; 9(7):525–31. https://doi.org/10.1093/ibd/ivv061 Epub 2015 Apr 19. PMID: 25895875.

35. Heida A, Park KT, van Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis. 2017 Jun; 23(6):894–902. https://doi.org/10.1097/MIB.0b013e3182810066 PMID: 28511198.

36. Gisbert JP, Bermejo F, Pérez-Calle JL, Taxonera C, Vera I, McNicholl AG, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009 Aug; 15(8):1190–8. https://doi.org/10.1002/ibd.20202 PMID: 19291780.

37. Zittan E, Kelly OB, Kirsch R, Milgrom R, Burns J, Nguyen GC, et al. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn’s Disease. Inflamm Bowel Dis. 2016 Mar; 22(3):623–30. https://doi.org/10.1097/MIB.0000000000000652 PMID: 26829406.

38. Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013 Feb; 19(2):332–41. https://doi.org/10.1097/MIB.0b013e3182810066 PMID: 23328771.

39. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014 Jun; 8(6):443–68. https://doi.org/10.1016/j.crohns.2013.12.013 Epub 2014 Mar 6. PMID: 24613021.

40. Reddy JG, Loftus EV Jr. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006; 35:837–55. https://doi.org/10.1016/j.gtc.2006.09.008 PMID: 17129816.

41. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52–65. https://doi.org/10.1053/j.gastro.2006.11.041 Epub 2006 Nov 29. PMID: 17241859.